UK Scientists Develop New Drug for Malaria

The drug can be used to treat adults and children weighing more than 5 kg. Data from a phase III study demonstrated significantly higher cure rates, compared to sulfadoxine-pyrimethamine (S/P) and was well tolerated. Anemia occurred in a small proportion of patients but was of limited duration. The drug has a short half-life, which creates a short "resistance selection window” that should help preserve its anti-malarial efficacy.

The drug is to be marketed by GlaxoSmithKline (GSK, London, UK). The malaria strategy recommended by the World Health Organization (WHO) for Africa to increase efficacy and reduce resistance is to use anti-malarials in combination with artemisinin to form a combination therapy. The development of Lapdap in a fixed dose artimisinin combination is under way.

"Drugs used as first-line treatment in uncomplicated P falciparum malaria, such as S/P, are failing because of increasing parasite resistance,” noted Prof. Peter Winstanley, directory of the Wellcome Trust Tropical Center at the University of Liverpool (UK), who led development work on the drug.





Related Links:
GlaxoSmithKline
University of Liverpool